Evidence map›Paper›PMID 29519866›Full record

Trial reportHaematologica2018

Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study.

Guillaume Cartron, Rémi Letestu, Caroline Dartigeas, Mira Tout, Béatrice Mahé, Anne-Laure Gagez, Emmanuelle Ferrant, Boris Guiu, Bruno Villemagne, Phan Letuan and 12 more

Abstract readClinical Trial, Phase IILetterRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Guillaume CartronDepartment of clinical hematology, University hospital of Montpellier, France g-cartron@chu-montpellier.fr.
Rémi LetestuAPHP, HUPSSD, Hospital Avicenne, Department of biological hematology, Bobigny, France.
Caroline DartigeasDepartment of clinical hematology, University hospital of Tours, France.
Mira ToutCNRS UMR 7292, François Rabelais University, University hospital of Tours, France.
Béatrice MahéDepartment of clinical hematology, University hospital of Nantes, France.
Anne-Laure GagezDepartment of clinical hematology, University hospital of Montpellier, France.
Emmanuelle FerrantDepartment of clinical hematology, University hospital of Dijon, France.
Boris GuiuDepartment of Radiology, University hospital of Montpellier, France.
Bruno VillemagneDepartment of hematology-oncology, Departmental Hospital La Roche-sur-Yon, France.
Phan LetuanLaboratory of Biostatistics, University institute of Clinical Research, Montpellier, France.
Thérèse AurranPaoli Calmette Center, Marseille, France.
Frédérique Orsini-PiocelleDepartment of clinical hematology, Hospital of Annecy, France.
Anne BanosDepartment of clinical hematology, Hospital Côte Basque, Bayonne, France.
Pierre FeugierDepartment of clinical hematology, University hospital of Nancy, France.
Véronique LeblondDepartment of clinical hematology, UPMC University of Paris 6, GRC11, Hospital La Pitié Salpêtrière, France.
Sophie de GuibertDepartment of clinical hematology, University hospital of Rennes, France.
Olivier TournilhacDepartment of clinical hematology, University hospital of Clermont-Ferrand, France.
Jehan DupuisFonctional unit Lymphoid malignancies, University hospital Henri Mondor, Créteil, France.
Alain DelmerDepartment of clinical hematology, University hospital of Reims, Rouen, France.
Valérie RouilléDepartment of clinical hematology, University hospital of Montpellier, France.
David TernantCNRS UMR 7292, François Rabelais University, University hospital of Tours, France.
Stéphane LeprêtreInserm U1245 and department of hematology, Henri Becquerel Center and university of Normandy UNIROUEN, Rouen, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAdultAgedAntigens, CD20CyclophosphamideDose-Response Relationship, DrugFemaleFranceHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedRituximabTreatment OutcomeVidarabineYoung AdultAntigens, CD20CyclophosphamidefludarabineRituximabVidarabine

Identifiers

PMID29519866
PMCPMC6068027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.